Real-world impact of lymph node assessment on adjuvant management in p53-abnormal endometrial carcinoma: a retrospective multicenter cohort from Central Europe
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064211%3A_____%2F26%3AW0000063" target="_blank" >RIV/00064211:_____/26:W0000063 - isvavai.cz</a>
Result on the web
<a href="https://oadoi.org/10.1016/j.ijgc.2026.104633" target="_blank" >https://oadoi.org/10.1016/j.ijgc.2026.104633</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ijgc.2026.104633" target="_blank" >10.1016/j.ijgc.2026.104633</a>
Alternative languages
Result language
angličtina
Original language name
Real-world impact of lymph node assessment on adjuvant management in p53-abnormal endometrial carcinoma: a retrospective multicenter cohort from Central Europe
Original language description
Objective: To determine how often lymph node assessment alters post-operative risk classification or adjuvant therapy in p53-abnormal endometrial carcinoma and to calculate the number needed to stage to obtain 1 management-changing result. Methods: This multicenter retrospective study included patients with biopsy-confirmed p53-abnormal endometrial carcinoma who underwent pre-operative expert ultrasound, molecular classification, and definitive surgery. Pre-operative risk groups were based on ultrasound-assessed invasion and molecular subtype; post-operative groups incorporated final pathology and lymph node status. The number needed to stage was defined as the number of patients staged divided by the number with management-changing results. Results: Among 120 patients, lymph node status was evaluable in 107, with metastases identified in 19 (17.8%) cases. Concordance between pre-operative and postoperative risk groups was 84.2%. Reclassification occurred in 15.8% of patients and was driven entirely by uterine pathological findings. Lymph node findings altered guideline-based post-operative management in only 2 of 107 patients (1.9%; 95% confidence interval 0.2% to 6.6%), both through treatment de-escalation based on negative nodal status. No escalation of adjuvant therapy was triggered by nodal metastases. The number needed to stage was 53.5. Conclusions: In this multicenter cohort of p53-abnormal endometrial carcinoma, lymph node assessment had a limited impact on guideline-based post-operative management, with treatment decisions largely driven by molecular subtype and uterine pathological factors. Prospective, molecularly stratified studies are needed to clarify the optimal role of nodal staging in this patient population.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2026
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
ISSN
1048-891X
e-ISSN
1525-1438
Volume of the periodical
36
Issue of the periodical within the volume
5
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
6
Pages from-to
-
UT code for WoS article
001737485300001
EID of the result in the Scopus database
—